ALGORAE PHARMACEUTICALS LTD

0.005

+0.000

Volume:3.26M

Turnover:19.53K

Market Cap:8.44M

PE:-6.13

High:0.006

Open:0.006

Low:0.005

Close:0.005

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Algorae Pharma’s drug AI-168 shows cardioprotection, outperforms beta blockers in pre-clinical studies of proliferation

Small Caps

·

29 Nov 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/1AI.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"1AI.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","market":"AU","secType":"STK","nameCN":"ALGORAE PHARMACEUTICALS LTD","latestPrice":0.005,"timestamp":1741151520000,"preClose":0.005,"halted":0,"volume":3255772,"delay":0,"changeRate":0,"change":0,"floatShares":1045460672,"shares":1687394731,"eps":-0.000815,"lyrEps":-0.00126,"pbRate":3.53,"amount":19525,"amplitude":0.2,"volumeRatio":6.01130041273598,"dividePrice":0,"prevYearClose":0.006,"fiveDayClose":0.006,"twentyDayClose":0.006},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","floatShares":1045460672,"roa":"-14.71%","roe":"-43.16%","lyrEps":-0.00126,"volumeRatio":6.01130041273598,"shares":1687394731,"dividePrice":0,"high":0.006,"amplitude":0.2,"preClose":0.005,"low":0.005,"week52Low":0.005,"pbRate":"3.53","psRate":"67.39","week52High":0.013,"institutionHeld":0,"latestPrice":0.005,"eps":-0.000815,"divideRate":0,"volume":3255772,"delay":0,"ttmEps":-0.000815,"open":0.006,"prevYearClose":0.006,"prevWeekClose":0.006,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.006,"twentyDayClose":0.006,"sixtyDayClose":0.008},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/1AI.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"1AI.AU\",market:\"AU\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/1AI.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"1AI.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507577995","title":"Algorae Pharmaceuticals advances R&D pipeline as AI-driven drug trials continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507577995","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507577995?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:33","pubTimestamp":1738117993,"startTime":"0","endTime":"0","summary":"Novel treatment development company Algorae Pharmaceuticals  says it is well placed to advance its innovative therapeutic pipeline and artificial intelligence -driven drug discovery plans.In releasing its quarterly results, the company said it is in a strong financial position with $2.4 million in cash as of 31 December 2024, providing sufficient funding for its planned activities.Priorities will include the continued evaluation of drug targets generated by the company’s proprietary AI platform AlgoraeOS and the progression of clinical trial planning.A major focus will be the initiation of in vivo studies for Algorae’s AI-168 treatment for cardiovascular disease.Among the company’s recent highlights was the demonstration of AI-168’s strong cardioprotective effects in preclinical studies conducted at the Victorian Heart Institute at Monash University.In studies comparing AI-168 against FDA-approved beta-blockers across multiple cardiovascular disease models, AI-168 was found to restore ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Algorae-Pharmaceuticals-ASX-1AI-December-2024-quarterly-results.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Algorae-Pharmaceuticals-ASX-1AI-December-2024-quarterly-results.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-research-development-ai-driven-drug-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2487612135","title":"Weekly wrap: record highs followed by a slight slip","url":"https://stock-news.laohu8.com/highlight/detail?id=2487612135","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487612135?lang=en_us&edition=fundamental","pubTime":"2024-11-30 00:30","pubTimestamp":1732897809,"startTime":"0","endTime":"0","summary":"The Australian share market had another positive week, reaching fresh record highs twice before slipping back a little in Friday trade.By the close on Friday the ASX 200 Index was down 0.1% or 8.1 points to 8436.2, as seven of the 11 sectors fell.That followed on from Thursday’s fresh record high of 8444.3 points and meant the index still closed 0.5% higher for the week.Two of the big heroes of Thursday’s rally – heavyweights Commonwealth Bank  and blood products group CSL  set the scene by shedding some of their gains, with CSL’s 1% fall to $282.22 the most severe.Property companies were among the hardest hit by the slide, down 0.7% overall with Scentre’s  1.1% fall to $3.68 and Goodman Group’s  0.8% fall to $37.91 some of the more notable.The influential banking sector also fell, making it difficult for the ASX 200 to produce a positive result.One individual share that reacted to news was almond producer Select Harvests , with shares falling 5.4% to $3.69.","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Record-highs-slight-slip-ASX-Nov-2024.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Record-highs-slight-slip-ASX-Nov-2024.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/weekly-wrap-record-highs-followed-by-slight-slip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7162","CBA.AU","BK7505","BK7070","CSL.AU","BK7137","BK7005","BK7511","BK7099","GCM.AU","BK7135","BK7117","BK7501","XKO.AU","SHV.AU","BK7508","XAO.AU","XJO.AU","SGR.AU","BK7028","CKF.AU","BP8.AU","MTS.AU","BK7155","BK7067","SCG.AU","1AI.AU","WEB.AU","BK7095","WJL.AU","BK7078","GMG.AU","PHO.AU","BK7510"],"gpt_icon":1},{"id":"2487695372","title":"BUZZ-Australia's Algorae Pharmaceuticals gains after positive drug assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2487695372","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487695372?lang=en_us&edition=fundamental","pubTime":"2024-11-29 10:27","pubTimestamp":1732847259,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Algorae Pharmaceuticals gains after positive drug assessment** Shares of Algorae Pharmaceuticals 1AI.AX rise as much 14.35 to A$0.008, their highest levels since Nov 21     ** The pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3N3N005A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2487710063","title":"Algorae Pharma’s drug AI-168 shows cardioprotection, outperforms beta blockers in pre-clinical studies of proliferation","url":"https://stock-news.laohu8.com/highlight/detail?id=2487710063","media":"Small Caps","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487710063?lang=en_us&edition=fundamental","pubTime":"2024-11-29 09:33","pubTimestamp":1732843980,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals  has announced positive results from pre-clinical studies evaluating the protective qualities of its cardiovascular drug candidate AI-168.The pre-clinical assessments at the Monash Victorian Heart Institute in Melbourne were designed to further evaluate the drug’s formulation and compare its performance with beta blockers using well-established in vitro models of cardiovascular disease.The results demonstrated strong cardioprotective qualities, outperforming existing first-line approved beta blockers in three cardiovascular cell lines used to assess the dysregulation of cell growth caused by common cardiac stressors PDGF and angiotensin II.When treated with AI-168, those cells effectively restored normal cell proliferation after 48 hours.AI-168 will continue to be assessed for medical indications where beta blockers are commonly prescribed—including hypertension, angina, heart failure and arrhythmias, among others.Algorae’s pre-clinical studies on AI-168 have cu","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharma-ASX-1AI-drug-AI-168-cardioprotection-beta-blockers.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharma-ASX-1AI-drug-AI-168-cardioprotection-beta-blockers.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharma-drug-ai-168-cardioprotection-outperforms-beta-blockers-pre-clinical-studies-proliferation/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["1AI.AU","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13}]}}